Clinical Trial Update: MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM [Phase 1]

View source ↗

Summary

Phase 1 MAD study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of PB-119 in adults with Type 2 Diabetes Mellitus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• PB-119 (PB-119)

Snippet

Sponsor: PegBio Co., Ltd. | Conditions: Type2 Diabetes Mellitus | Phase 1 | Status: COMPLETED